The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

Discover the latest addition to Children's Hospital Los Angeles' 10 cell and gene therapy treatments, including Casgevy for sickle cell disease ...

The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...

Clinical trials for exa-cel have shown promising results that it has been authorised by the FDA and MHRA for use in beta thalassemia and sickle cell disease. These successes make CRISPR technology, as ...

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...

Global Thalassemia Market Global Thalassemia Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...